Stimulant treatment with methylphenidate (MPH) and amphetamines (AMP) is first-line for children and adolescents with attention-deficit/hyperactivity disorder (ADHD), but quantitative guidance on comparative efficacy and dose selection within licensed dose ranges remains limited. This study aimed to compare dose-response relationships for MPH and AMP and identify dose ranges that balance symptom improvement and adverse event-related discontinuation across benefit-risk preferences. CENTRAL,…
